BMRN vs. BNTX: BioMarin Pharmaceutical vs. BioNTech Stock Comparison
How do BioMarin Pharmaceutical (BMRN) and BioNTech (BNTX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioMarin Pharmaceutical (BMRN) and BioNTech (BNTX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
BioMarin Pharmaceutical (BMRN) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | BMRN | BNTX |
|---|---|---|
| Name | BioMarin Pharmaceutical Inc. | BioNTech SE American Depositary Share |
| Country/Region | United States | Germany |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 10.85 billion USD | 21.70 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 26, 1999 | October 10, 2019 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BMRN | BNTX |
|---|---|---|
| Total Return (1Y) | 8.82% | -14.78% |
| Total Return (3Y, Annualized) | -12.54% | -3.99% |
| Total Return (5Y, Annualized) | -7.51% | -17.02% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
BioNTech (BNTX) has an aggressive beta of 1.30, indicating higher sensitivity to broad-market moves, while BioMarin Pharmaceutical (BMRN) is defensive at 0.24 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
| Metric | BMRN | BNTX |
|---|---|---|
| Volatility (1Y, Annualized) | 35.50% | 47.44% |
| Beta (5Y) | 0.24 | 1.30 |
| Max Drawdown (5Y) | -57.64% | -78.10% |
| Avg. Volume (3M) | 2.28M | 1.21M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BMRN | BNTX |
|---|---|---|
| Sharpe Ratio (1Y) | 0.13 | -0.40 |
| Sortino Ratio (1Y) | 0.23 | -0.59 |
Profitability
ROE (TTM)
Both BioMarin Pharmaceutical (BMRN) at -0.31% and BioNTech (BNTX) at -8.14% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.14%
- Max
- 109.18%
- Q3
- 6.23%
- BNTX
- -8.14%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both BioMarin Pharmaceutical (BMRN) at -0.52% and BioNTech (BNTX) at -60.87% report negative net margin values, usually indicating net losses over the period.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-60.87%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BNTX
- -60.87%
Operating Margin (TTM)
Both BioMarin Pharmaceutical (BMRN) at 26.58% and BioNTech (BNTX) at 30.28% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.28%
- Max
- 83.12%
- BNTX
- 30.28%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BMRN | BNTX |
|---|---|---|
| ROE (TTM) | -0.31% | -8.14% |
| ROA (TTM) | 3.89% | -4.04% |
| Net Margin (TTM) | -0.52% | -60.87% |
| Operating Margin (TTM) | 26.58% | 30.28% |
| Gross Margin (TTM) | 53.21% | 76.73% |
Growth
Revenue Growth
Both BioMarin Pharmaceutical (BMRN) at 12.87% and BioNTech (BNTX) at 4.32% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; BioNTech (BNTX) has no EPS growth figure this period.
Growth Metrics
| Metric | BMRN | BNTX |
|---|---|---|
| Revenue Growth (YoY) | 12.87% | 4.32% |
| Revenue Growth (3Y CAGR) | 15.40% | -45.06% |
| EPS Growth (YoY) | -18.55% | -- |
| EPS Growth (3Y CAGR) | 33.89% | -- |
Financial Strength
Current Ratio (MRQ)
BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while BioMarin Pharmaceutical (BMRN) at 2.44 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMRN.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.55
- Max
- 25.13
- Q3
- 12.13
- BNTX
- 8.55
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
BioNTech (BNTX) at 0.02 keeps leverage in the lower quartile, while BioMarin Pharmaceutical (BMRN) at 0.67 sits in the higher-leverage quartile.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- BNTX
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BMRN | BNTX |
|---|---|---|
| Current Ratio (MRQ) | 2.44 | 8.55 |
| Debt / Equity (MRQ) | 0.67 | 0.02 |
| Net Debt / EBITDA | 4.04 | -- |
Dividends
Dividend Yield (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor BioNTech (BNTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BNTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor BioNTech (BNTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BNTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BMRN | BNTX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor BioNTech (BNTX) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BNTX
- --
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while BioNTech (BNTX) at 8.96 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.96
- Max
- 58.18
- Q3
- 25.77
- BNTX
- 8.96
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile against book while BioMarin Pharmaceutical (BMRN) at 1.73 is valued near its industry’s middle — BNTX is cheaper on assets, though weigh it against ROE and asset quality.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.09
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BNTX
- 1.09
- Min
- -5.59
Valuation Metrics
| Metric | BMRN | BNTX |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 2.97 | 8.96 |
| P/B Ratio (MRQ) | 1.73 | 1.09 |
| Free Cash Flow Yield (TTM) | -0.15% | -7.34% |